Literature DB >> 3900614

Dopamine D-2 receptor-mediated excitation of caudate nucleus neurons from the substantia nigra.

Y Ohno, M Sasa, S Takaori.   

Abstract

Microiontophoretic studies using cats anesthetized with alpha-chloralose were performed to elucidate whether the excitatory response of caudate nucleus (CN) neurons upon stimulation of the pars compacta of the substantia nigra (SN) is mediated by the dopamine D-1 or D-2 receptor. There were rare convergent inputs from the SN and motor cortex (MC) in the CN neurons. Iontophoretic application of haloperidol and domperidone (dopamine D-2 receptor antagonist) produced dose-dependent inhibition of spikes elicited by SN stimulation in 25 of 42 and 50 of 82 CN neurons, respectively, however, no alterations of spikes elicited by MC stimulation occurred in any 11 neurons tested. Iontophoretically applied SCH 23390 (D-1 antagonist) did not inhibit the SN-induced spikes in any CN neurons, of which spikes were inhibited by domperidone. These results suggest that the SN-induced spikes are mediated by dopamine, which acts on postsynaptic D-2 receptors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3900614     DOI: 10.1016/0024-3205(85)90183-3

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

1.  In vivo receptor binding, neurochemical and functional studies with the dopamine D-1 receptor antagonist SCH23390.

Authors:  S Hjorth; A Carlsson
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

2.  Action of intravenously administered talipexole on the rat striatal neurons receiving excitatory input from nigral dopamine neurons.

Authors:  H Matsubayashi; T Amano; Y Hongjing; Y Kohno; M Sasa
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

3.  The effects of methylphenidate on cerebral activations to salient stimuli in healthy adults.

Authors:  Olivia M Farr; Sien Hu; David Matuskey; Sheng Zhang; Osama Abdelghany; Chiang-Shan R Li
Journal:  Exp Clin Psychopharmacol       Date:  2013-11-04       Impact factor: 3.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.